Literature DB >> 16099945

Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis).

Shinsuke Umeda1, Michihiro T Suzuki, Haru Okamoto, Fumiko Ono, Atsushi Mizota, Keiji Terao, Yasuhiro Yoshikawa, Yasuhiko Tanaka, Takeshi Iwata.   

Abstract

We have previously reported a cynomolgus monkey (Macaca fascicularis) pedigree with early onset macular degeneration that develops drusen at 2 yr after birth. In this study, the molecular composition of drusen in monkeys affected with late onset and early onset macular degeneration was both characterized. Involvement of anti-retinalautoimmunity in the deposition of drusen and the pathogenesis of the disease was also evaluated. Funduscopic and histological examinations were performed on 278 adult monkeys (mean age=16.94 yr) for late onset macular degeneration. The molecular composition of drusen was analyzed by immunohistochemistry and/or direct proteome analysis using liquid chromatography tandem mass spectroscopy (LC-MS/MS). Anti-retinal autoantibodies in sera were screened in 20 affected and 10 age-matched control monkeys by Western blot techniques. Immunogenic molecules were identified by 2D electrophoresis and LC-MS/MS. Relative antibody titer against each antigen was determined by ELISA in sera from 42 affected (late onset) and 41 normal monkeys. Yellowish-white spots in the macular region were observed in 90 (32%) of the late onset monkeys that were examined. Histological examination demonstrated that drusen or degenerative retinal pigment epithelium (RPE) cells were associated with the pigmentary abnormalities. Drusen in both late and early onset monkeys showed immunoreactivities for apolipoprotein E, amyloid P component, complement component C5, the terminal C5b-9 complement complex, vitronectin, and membrane cofactor protein. LC-MS/MS analyses identified 60 proteins as constituents of drusen, including a number of common components in drusen of human age-related macular degeneration (AMD), such as annexins, crystallins, immunoglobulins, and complement components. Half of the affected monkeys had single or multiple autoantibodies against 38, 40, 50, and 60 kDa retinal proteins. The reacting antigens of 38 and 40 kDa were identified as annexin II and mu-crystallin, respectively. Relative antibody titer against annexin II in affected monkeys was significantly higher than control animals (P<0.01). Significant difference was not observed in antibody titer against mu-crystallin; however, several affected monkeys showed considerably elevated titer (360-610%) compared with the mean for unaffected animals. Monkey drusen both in late and early onset forms of macular degeneration had common components with drusen in human AMD patients, indicating that chronic inflammation mediated by complement activation might also be involved in the formation of drusen in these affected monkeys. The high prevalence of anti-retinalautoantibodies in sera from affected monkeys demonstrated an autoimmune aspect of the pathogenesis of the disease. Although further analyses are required to determine whether and how autoantibodies against annexin II or mu-crystallin relate to the pathogenesis of the disease, it could be hypothesized that immune responses directed against these antigens might trigger chronic activation of the complement cascade at the site of drusen formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099945     DOI: 10.1096/fj.04-3525fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  73 in total

1.  Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.

Authors:  Mausumi Bandyopadhyay; Bärbel Rohrer
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-18       Impact factor: 4.799

Review 2.  Animal models of age related macular degeneration.

Authors:  Mark E Pennesi; Martha Neuringer; Robert J Courtney
Journal:  Mol Aspects Med       Date:  2012-06-15

3.  Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells.

Authors:  Qingning Bian; Shasha Gao; Jilin Zhou; Jian Qin; Allen Taylor; Elizabeth J Johnson; Guangwen Tang; Janet R Sparrow; Dennis Gierhart; Fu Shang
Journal:  Free Radic Biol Med       Date:  2012-06-23       Impact factor: 7.376

Review 4.  Age-related macular degeneration and the immune response: implications for therapy.

Authors:  Robert B Nussenblatt; Frederick Ferris
Journal:  Am J Ophthalmol       Date:  2007-08-15       Impact factor: 5.258

Review 5.  Surgical approaches to gene and stem cell therapy for retinal disease.

Authors:  J Timothy Stout; Peter J Francis
Journal:  Hum Gene Ther       Date:  2011-05       Impact factor: 5.695

Review 6.  The use of SD-OCT in the differential diagnosis of dots, spots and other white retinal lesions.

Authors:  Elena Zaharova; Jerome Sherman
Journal:  Eye Brain       Date:  2011-10-25

Review 7.  Functions of crystallins in and out of lens: roles in elongated and post-mitotic cells.

Authors:  Christine Slingsby; Graeme J Wistow
Journal:  Prog Biophys Mol Biol       Date:  2014-02-28       Impact factor: 3.667

8.  Ocular proteomics with emphasis on two-dimensional gel electrophoresis and mass spectrometry.

Authors:  Bent Honoré; Henrik Vorum; Nakul Mandal; Steffen Heegaard; Jan Ulrik Prause
Journal:  Biol Proced Online       Date:  2009-12-24       Impact factor: 3.244

9.  Microarray analysis of differentially expressed genes in the brains of tubby mice.

Authors:  Jeong Ho Lee; Chul Hoon Kim; Dong Goo Kim; Young Soo Ahn
Journal:  Korean J Physiol Pharmacol       Date:  2009-04-30       Impact factor: 2.016

10.  Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD.

Authors:  Wenxin Ma; Lian Zhao; Aurora M Fontainhas; Robert N Fariss; Wai T Wong
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.